002370.SHE Zhejiang Yatai Pharmaceutical Co Ltd
- Market cap
- CNY 3.30B
- P/E
- -
- P/B
- 2.97x
- ROE
- -1.7%
- Dividend yield
- 1.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002370.SHE undervalued?
Graham numberThe Graham number of Zhejiang Yatai Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Yatai Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Yatai Pharmaceutical Co Ltd yet.
Zhejiang Yatai Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Yatai Pharmaceutical Co Ltd
Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid dosage, cephalosporin powder injection, and freeze-dried powder injection products. It also provides antibiotic and non-antibiotic drugs. The company was founded in 1989 and is based in Shaoxing, China.
Full company profileZhejiang Yatai Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Yatai Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 863M | 1.08B | 1.31B | 708M | 515M | 315M | 373M | 421M | 405M | 323M | 291M |
| Gross Profit | 340M | 482M | 575M | 224M | 253M | 105M | 126M | 132M | 121M | 107M | 93.6M |
| Operating Income | 135M | 237M | 241M | -1.92B | 51.1M | -199M | -117M | -63.5M | 28.2M | -12.2M | -14.0M |
| EBITDA | 206M | 277M | 300M | -1.81B | 146M | -125M | -42.6M | 74.4M | 97.4M | 163M | -21.3M |
| Net Income | 125M | 202M | 208M | -1.92B | 27.3M | -228M | -133M | -11.9M | 34.2M | 96.3M | -19.0M |
| EPS | 0.28 | 0.38 | 0.39 | -3.58 | 0.05 | -0.43 | -0.25 | -0.02 | 0.05 | 0.13 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 2.43B | 2.85B | 3.54B | 2.27B | 1.96B | 1.61B | 1.52B | 1.43B | 1.40B | 1.28B | 1.22B |
| Total Liabilities | 266M | 570M | 1.16B | 1.64B | 1.30B | 1.18B | 1.22B | 848M | 430M | 159M | 122M |
| Shareholders' Equity | 2.16B | 2.27B | 2.36B | 633M | 660M | 433M | 301M | 581M | 972M | 1.12B | 1.09B |
| Cash & Short-term Investments | 814M | 767M | 534M | 1.18B | 903M | 821M | 758M | 720M | 744M | 619M | 339M |
| Total Debt | - | 40.0M | 264M | 1.05B | 1.01B | 974M | 952M | 690M | 30.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -38.0M | 128M | 37.0M | -55.7M | 17.8M | -3.84M | 12.0M | 14.7M | 24.4M | 28.9M | - |
| Capital Expenditure | 75.9M | 283M | 631M | 295M | 39.1M | 15.8M | 21.1M | 7.46M | 9.92M | 5.05M | 16.0M |
| Free Cash Flow | -114M | -155M | -594M | -351M | -21.3M | -19.6M | -9.06M | 7.19M | 14.4M | 23.8M | -175M |
| Ratios | |||||||||||
| ROE | 5.8% | 8.9% | 8.8% | -303.4% | 4.1% | -52.7% | -44.1% | -2.0% | 3.5% | 8.6% | -1.7% |
| ROA | 5.2% | 7.1% | 5.9% | -84.7% | 1.4% | -14.2% | -8.7% | -0.8% | 2.4% | 7.5% | -1.6% |
| Net Profit Margin | 14.5% | 18.7% | 15.9% | -271.3% | 5.3% | -72.4% | -35.5% | -2.8% | 8.5% | 29.8% | -6.5% |
| Debt to Equity | - | 0.02x | 0.11x | 1.65x | 1.54x | 2.25x | 3.16x | 1.19x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Yatai Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.13%
- Forward dividend
- -
- Payout ratio
- 38.8%
- Ex-dividend date
- Jun 10, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 37.4M | 0.05 | 38.8% |
| 2024 | CNY 11.9M | 0.02 | 34.8% |
| 2023 | CNY 16.5M | 0.03 | - |
| 2022 | CNY 13.9M | 0.03 | - |
| 2021 | CNY 13.3M | 0.03 | - |
| 2020 | CNY 15.0M | 0.03 | 55.0% |
| 2019 | CNY 44.4M | 0.08 | - |
| 2018 | CNY 61.4M | 0.12 | 29.5% |
| 2017 | CNY 28.2M | 0.05 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Sep 20, 2017.
Who owns Zhejiang Yatai Pharmaceutical Co Ltd
- Insiders 19.93%
- Institutions 0.00%
- Public & others 80.08%
- Shares outstanding 746M
- Free float 634M
Zhejiang Yatai Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Yatai Pharmaceutical Co Ltd
- Ticker
- 002370.SHE
- ISIN
- CNE100000MM5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 16, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 511
- Fiscal year end
- December
- Address
- No. 36, Nanbin West Road, Shaoxing, China, 312366
- Phone
- 86 575 8481 5472
- Website
- ytyaoye.com
About Zhejiang Yatai Pharmaceutical Co Ltd
Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid dosage, cephalosporin powder injection, and freeze-dried powder injection products. It also provides antibiotic and non-antibiotic drugs. The company was founded in 1989 and is based in Shaoxing, China.
Zhejiang Yatai Pharmaceutical Co Ltd management
4- Mr. Xiaobiao ChenCFO, Head of Accounting Department & Employee Representative Director · born 1984
- Mr. Qin Shui TanDeputy General Manager · born 1970
- Mr. Zhongxun QiuChairman & GM · born 1998
- Mr. Hao ZongBoard Secretary & Non-Independent Director · born 1989